A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen MK-5172 and MK-8742 ± Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection

Trial Profile

A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen MK-5172 and MK-8742 ± Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Elbasvir (Primary) ; Grazoprevir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms C-WORTHY
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 25 Oct 2017 This trial has been discontinued in Germany
    • 10 Feb 2017 Results of an integrated analysis of this trial and 5 other trails (see profiles 242414, 243158, 243227, 243234, 243273) published in the Gastroenterology
    • 29 Jul 2016 According to a Merck media release, Zepatier (elbasvir/grazoprevir) with or without ribavirin has been approved in the European Union for the treatment of chronic hepatitis C virus genotype 1-4 infections in adults.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top